ArticleFrontiers in endocrinology2025
Thyroid autoimmunity at onset of type 1 diabetes as a predictor of thyroid dysfunction: a thirty-years retrospective longitudinal study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid autoimmunity commonly coexists with type 1 diabetes due to shared autoimmune mechanisms, and early recognition of thyroid dysfunction is crucial for optimizing metabolic control. However, there is no consensus regarding the optimal screening strategy for detecting thyroid disease in patients with type 1 diabetes. This study aimed to determine the long-term predictive value of thyroid peroxidase antibodies (TPO-Abs) at the onset of type 1 diabetes for the development of thyroid dysfunction and to evaluate the influence of age at diabetes onset. Methods: We conducted a retrospective longitudinal study at a tertiary university hospital in Barcelona, Spain, including 160 Caucasian patients consecutively diagnosed with type 1 diabetes between 1987 and 1994. All participants were followed for at least 10 years (mean follow-up 30.6 ± 4.5 years). TPO-Abs were measured at diabetes onset, and thyroid function was periodically assessed throughout follow-up. The incidence of thyroid dysfunction was analyzed according to TPO-Ab status and age at diabetes onset (<18 vs ≥18 years). Results: At diabetes diagnosis, 21.9% of patients were TPO-Abs positive. Antibody positivity was a strong predictor of thyroid dysfunction, conferring an eightfold increased risk compared with antibody-negative patients (RR 8.1, 95% CI 4.79-13.69, p<0.001). During follow-up, thyroid dysfunction also developed in initially antibody-negative patients, particularly in those diagnosed before 18 years of age, whereas cases were rare among those diagnosed in adulthood. The relative risk of thyroid dysfunction associated with TPO-Abs at diabetes onset was substantially higher in adults compared with youth (RR 12.6, 95% CI 6.10-25.81 vs. RR 3.4, 95% CI 1.35-8.71). Conclusion: A rational screening strategy for thyroid disease in asymptomatic patients with type 1 diabetes should include measurement of TPO-Abs and thyrotropin at diagnosis, followed by annual thyrotropin assessment in antibody-positive individuals. In patients diagnosed with type 1 diabetes before 18 years of age who are initially antibody-negative, repeat screening every two years from puberty through adulthood is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.